Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ovarian artery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Ovarian artery. Displaying page 1 of 1.
    EudraCT Number: 2011-001516-54 Sponsor Protocol Number: GS-US-259-0103 Start Date*: 2011-11-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging.
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004780-71 Sponsor Protocol Number: PROFERTIL Start Date*: Information not available in EudraCT
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase III Randomized Double-Blinded Placebo-Controlled Study of Use of GnRHa during Chemotherapy for Fertility Protection of Young Women and Teenagers with Cancer - ProFertil
    Medical condition: Breast Cancer Acute Leukemia Lymphomas (Hodgkin and non-Hodgkin) Sarcomas (Osteo, Soft tissue and Ewing)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005092-24 Sponsor Protocol Number: FSJD-PIOSPIMET-2015 Start Date*: 2016-01-22
    Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU
    Full Title: A prospective, open-label, randomized, two-armed clinical trial to evaluate the efficacy and safety of a combination of ethinyl-estradiol and levonorgestrel versus a low-dose combination of pioglit...
    Medical condition: ovarian hyperandrogenism with hyperinsulinaemia
    Disease:
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004362-34 Sponsor Protocol Number: A1481324 Start Date*: 2015-08-26
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) RO (Completed) PL (Completed) GR (Completed) NL (Completed) PT (Completed) HR (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-003177-99 Sponsor Protocol Number: A3921133 Start Date*: 2014-07-10
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) FI (Completed) NL (Completed) SK (Completed) GB (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000478-20 Sponsor Protocol Number: B1481045 Start Date*: 2014-10-21
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED ...
    Medical condition: Primary Hyperlipidemia or mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020667 Hyperlipidemia LLT
    17.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) SE (Completed) CZ (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002644-87 Sponsor Protocol Number: B1481021 Start Date*: 2013-11-27
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED,PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLE...
    Medical condition: Heterozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) NL (Completed) NO (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002642-37 Sponsor Protocol Number: B1481019 Start Date*: 2014-01-24
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPID...
    Medical condition: primary hyperlipidemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10020667 Hyperlipidemia LLT
    18.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001724-35 Sponsor Protocol Number: AMASCIS-02 Start Date*: 2020-06-16
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP)
    Full Title: AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL.
    Medical condition: Moderate-severe ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004266-40 Sponsor Protocol Number: ICORG 06-32/NSABP B-42 Start Date*: 2007-11-02
    Sponsor Name:ICORG
    Full Title: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxife...
    Medical condition: Hormone Receptor Positive Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001464-23 Sponsor Protocol Number: A1481243 Start Date*: 2006-06-08
    Sponsor Name:Pfizer Ltd,Ramsgate Road,Sandwich CT13 9NJ
    Full Title: A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects , aged 18 ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000394-21 Sponsor Protocol Number: A6301094 Start Date*: 2016-07-20
    Sponsor Name:Pfizer Inc
    Full Title: A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES.
    Medical condition: Acute treatment and secondary prophylaxis of recurrent VTE (venous thromboembolism) in children with or without cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) SI (Completed) PL (Completed) GB (Completed) DE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000762-11 Sponsor Protocol Number: 62113-55115 Start Date*: 2014-10-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxoru...
    Medical condition: High Grade Undifferentiated Uterine Sarcoma (HGUS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046821 Uterine sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002440-14 Sponsor Protocol Number: AC-055-302 Start Date*: 2008-05-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomati...
    Medical condition: To assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) FR (Completed) FI (Completed) SE (Completed) AT (Completed) DK (Completed) SK (Completed) PT (Prematurely Ended) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002646-36 Sponsor Protocol Number: B1481022 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) SE (Completed) SK (Prematurely Ended) ES (Completed) IT (Completed) BE (Prematurely Ended) DK (Completed) PL (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002795-41 Sponsor Protocol Number: B1481038 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) SK (Prematurely Ended) ES (Completed) BE (Prematurely Ended) DK (Completed) SE (Completed) IE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:54:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA